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COMMENT&RESPONSE
Guidelines forManagingHigh Blood Pressure
To the Editor Someevidence against β-blockers1 has beenpub-
lished in recent years; however, the exclusion of these drugs
as initial treatment of uncomplicated hypertension in the re-
port fromthepanelmembersappointed to theEighth JointNa-
tional Committee (JNC 8)2 is surprising.
First, the evidence against atenololwas presented in only
1 study, the Losartan Intervention for Endpoint Reduction in
Hypertension Study (LIFE),3 and the quality of this evidence
was classified asweak by the panel. Results fromLIFE cannot
be extrapolated to the general population because the pa-
tients included were a high-risk sample with ventricular hy-
pertrophybyelectrocardiographyandahighprevalenceofdia-
betes mellitus (13%) and cardiovascular disease (25%). Also,
the mean age in LIFE was 66.9 years, and it has been shown
that β-blockers can be more effective in patients with hyper-
tensionwho are younger than 60 years.4 In other studies that
analyzed a general population, the performance of β-block-
ers was similar to that of other drugs or the evidence was not
sufficient to draw conclusions.
Second, β-blockers differ substantially in their pharma-
cological properties in ways that may affect their relative ef-
ficacy and tolerability. Limitations of atenolol cannot be ex-
trapolated to third-generation β-blockers (eg, carvedilol and
nebivolol), which combine antihypertensive and vasodila-
tory properties. There are currently no mortality and cardio-
vascular event data on these vasodilating β-blockers as initial
therapy for hypertension.1
Third, in clinical trials, atenolol is typically a once-daily
therapy.However, this regimenmaynotprovidea full 24hours
ofbloodpressure (BP)control.Thisbiasmayexplain, inpart, the
reducedbenefit inpreventionofcardiovasculareventsattributed
to atenolol comparedwith other antihypertensive agents.5
If the majority of patients with hypertension will require
2 or more drugs to achieve control of their hypertension, the
concernaboutwhatantihypertensivedrugshouldbeused first
becomes lessurgent. Instead,wesuggestprioritizing the study
of combinations of antihypertensive drugs according to age,
weight, cost, availability, and other variables.
Alberto Morales-Salinas, MD, MPH
Antonio Coca, MD, PhD, FRCP
Fernando StuardoWyss, MD, PhD
Author Affiliations:Department of Cardiology, Cardiocentro “Ernesto Che
Guevara,” Santa Clara, Cuba (Morales-Salinas); Department of Internal Medicine,
University of Barcelona, Barcelona, Spain (Coca); Department of Cardiology,
Hospital General San Juan de Dios, Guatemala City, Guatemala (Wyss).
Corresponding Author: Alberto Morales-Salinas, MD, MPH, Cardiocentro
Ernesto Che Guevara, Colon 473, Estrada Plama yMisionero, Santa Clata, Villa
Clara 50100, Cuba (cardioams@yahoo.es).
Letters
jama.com JAMA July 16, 2014 Volume 312, Number 3 293
Downloaded From:  by a Universidad de Barcelona User  on 02/28/2018
Copyright 2014 American Medical Association. All rights reserved.
Conflict of Interest Disclosures: The authors have completed and submitted
the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were
reported.
1. Bangalore S, Steg G, Deedwania P, et al; REACH Registry Investigators.
β-Blocker use and clinical outcomes in stable outpatients with and without
coronary artery disease. JAMA. 2012;308(13):1340-1349.
2. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the
management of high blood pressure in adults: report from the panel members
appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311
(5):507-520.
3. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular
morbidity andmortality in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;
359(9311):995-1003.
4. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the
treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737-1742.
5. McGill JB. Optimal use of β-blockers in high-risk hypertension: a guide to
dosing equivalence. Vasc Health Risk Manag. 2010;6:363-372.
To theEditorTheguideline fromthepanel appointed to the JNC
81 recommended drug treatment to lower BP for patients
aged 60 years or older with systolic blood pressure (SBP)
of 150 mm Hg or greater or diastolic blood pressure (DBP) of
90mmHg or greater. For patients younger than 60 years, the
panel recommended medications for DBP of 90 mm Hg or
greater. Both of these recommendations were classified as
Grade A, presumably based on randomized clinical trials
(RCTs). However, a systematic review that we coauthored in
the Cochrane Database of Systematic Reviews2 found no evi-
dence supporting drug treatment for patients of any agewith
stage 1 (mild) hypertension (SBP of 140-159 mm Hg, DBP of
90-99 mm Hg, or both) and no previous cardiovascular dis-
ease (ie, primary prevention).
For the threshold recommendation for drug treatment for
patients aged 60 years or older, the JNC 8 panel cited 6 RCTs.
The first 3 were placebo-controlled RCTs (HYVET, Syst-Eur,
SHEP) that only included patients with stage 2 hypertension
(SBP ≥160 mm Hg) rather than stage 1 hypertension. Al-
thoughRCTsofpatientswith stage2hypertensionconfirmthe
effect of drugs for patientswith stage 2, they shouldnot be ex-
trapolated topeoplewithmildhypertension.Theother 3RCTs
(JATOS, VALISH, and CARDIO-SIS) included almost exclu-
sively patients with stage 2 hypertension and had no placebo
control groups. Without a no-treatment group, these studies
say nothing about the benefits and harms of drugs for low-
risk patients with mild hypertension.
For patients younger than60years, the JNC8authors ref-
erenced 5 RCTs as providing “high-quality evidence” to sup-
port their strong (GradeA) recommendation fordruguseabove
a DBP threshold of 90 mm Hg. All these trials mixed the re-
sultsofpatientswithstage 1and2hypertension.Of these trials,
our Cochrane review included the Medical Research Coun-
cil’s trial of drug treatment ofmild hypertension,3 theAustra-
lian Therapeutic Trial in Mild Hypertension,4 and the VA
Cooperative Study5 because we could obtain individual pa-
tientdataon treatmentandoutcomes.Amongthepatients rep-
resenting primary prevention with mild hypertension from
these trials, there was no proven benefit of drug treatment.
To be accurate, the latest guidelines for the thresholds for
drug treatment should change the strength of the recommen-
dation to Grade E (“expert opinion”). Better still, the thresh-
old for drug treatment recommendation shouldbe changed to
stage2hypertension (SBP>160mmHgandDBPof 100mmHg),
for which the strength could be appropriately graded as A.
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To the Editor The updated 2014 guidelines for the manage-
ment of high BP in adults by the panel appointed to the JNC
81 didnot consider issues relevant to sexdifferences inhyper-
tensive health. Variables of age and race were addressed, but
stratificationbysexwasomitted.Sex isadeterminantofhealth
outcomes, with differences inmetabolism, hormonalmilieu,
pharmacodynamics, pathophysiology, and therapeutic con-
siderations.
The issueof therapeutic options stratifiedby sex is of clear
importance.Althoughsomecontroversy remains regarding fe-
tal teratogenicity of angiotensin-converting enzyme (ACE) in-
hibitors and angiotensin receptor blockers (ARBs), given the
degreeof irreversible risk, thisneedstobeaconsiderationwhen
choosing pharmacological options for women at risk of be-
comingpregnant.Accordingto theEuropeanConsensusGuide-
lines for the management of hypertension, “In women with
child-bearingpotential, ACE inhibitors andangiotensin recep-
tor blockers should be avoided, due to possible teratogenic
effects.”2
In addition, Bullo et al3 stated, “Thirty years after the first
description of ACE-I fetopathy, relevant complications are, at
present, regularly described, indicating that the awareness of
the deleterious effect of prenatal exposure to drugs inhibit-
ing the renin-angiotensin system should be improved.” Until
such timeas there is definitive evidenceof safetyduringpreg-
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